Royal Fund Management LLC Acquires 4,357 Shares of Merck & Co., Inc. $MRK

Royal Fund Management LLC lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 6.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,200 shares of the company’s stock after acquiring an additional 4,357 shares during the quarter. Royal Fund Management LLC’s holdings in Merck & Co., Inc. were worth $7,285,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Abound Wealth Management boosted its position in Merck & Co., Inc. by 6.8% in the fourth quarter. Abound Wealth Management now owns 1,554 shares of the company’s stock worth $164,000 after purchasing an additional 99 shares during the last quarter. Pine Haven Investment Counsel Inc increased its position in shares of Merck & Co., Inc. by 0.7% during the 4th quarter. Pine Haven Investment Counsel Inc now owns 14,137 shares of the company’s stock valued at $1,488,000 after purchasing an additional 105 shares during the last quarter. Lake Street Private Wealth LLC raised its stake in shares of Merck & Co., Inc. by 2.1% during the 4th quarter. Lake Street Private Wealth LLC now owns 5,203 shares of the company’s stock worth $548,000 after purchasing an additional 109 shares during the period. One Charles Private Wealth Services LLC raised its stake in shares of Merck & Co., Inc. by 3.3% during the 3rd quarter. One Charles Private Wealth Services LLC now owns 3,464 shares of the company’s stock worth $291,000 after purchasing an additional 111 shares during the period. Finally, Fragasso Financial Advisors Inc boosted its holdings in shares of Merck & Co., Inc. by 1.0% in the 4th quarter. Fragasso Financial Advisors Inc now owns 11,502 shares of the company’s stock worth $1,211,000 after buying an additional 115 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. This trade represents a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the sale, the chief marketing officer owned 80,615 shares in the company, valued at $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is currently owned by insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage cholesterol pill delivered large LDL cuts (≈64.6%) and met its head‑to‑head primary endpoint — a potential new blockbuster oral option for lowering “bad” cholesterol that could materially diversify revenue beyond oncology. Merck’s drug reduced bad cholesterol by 64.6% in late-stage trial
• Positive Sentiment: Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) showed proof‑of‑concept in combined post‑ and precapillary pulmonary hypertension with HFpEF — opens a foothold in a hard heart‑failure segment and supports pipeline value. How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” and a $142 price target — a sizable upside vs. current levels that can support investor confidence and buying interest. Benzinga coverage
• Neutral Sentiment: Retail and media attention (e.g., Jim Cramer’s “stay the course” call) has driven momentum into Merck stock over recent months; that attention can amplify swings but is not a fundamental catalyst. Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course”
• Neutral Sentiment: Industry reports list Merck as a major player in the growing cutaneous squamous cell carcinoma market — underscores long‑term TAM but not an immediate stock driver. Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion
• Neutral Sentiment: New FY2026 earnings estimates and coverage updates are circulating (Erste Group Bank note) — watch revisions for guidance confirmation versus management’s FY2026 EPS range. FY2026 Earnings Estimate for MRK Issued By Erste Group Bank
• Negative Sentiment: Analysis flags an upcoming Keytruda patent cliff and Merck’s aggressive M&A push to refill the revenue gap — a strategic risk that could pressure sentiment if deal execution or integration falls short. Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff

Merck & Co., Inc. Stock Down 1.4%

Shares of NYSE MRK opened at $117.99 on Tuesday. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The business’s fifty day moving average price is $116.83 and its 200-day moving average price is $102.29. The stock has a market capitalization of $291.71 billion, a PE ratio of 16.21, a P/E/G ratio of 2.31 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the prior year, the company earned $1.72 EPS. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Wall Street Analysts Forecast Growth

MRK has been the subject of several research reports. The Goldman Sachs Group increased their price target on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. UBS Group boosted their target price on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Finally, Cantor Fitzgerald increased their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $127.13.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.